Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases
Background Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2021-03, Vol.124 (7), p.1294-1300 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1300 |
|---|---|
| container_issue | 7 |
| container_start_page | 1294 |
| container_title | British journal of cancer |
| container_volume | 124 |
| creator | Starzer, Angelika M. Steindl, Ariane Mair, Maximilian J. Deischinger, Carola Simonovska, Anika Widhalm, Georg Gatterbauer, Brigitte Dieckmann, Karin Heller, Gerwin Preusser, Matthias Berghoff, Anna S. |
| description | Background
Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial solid cancer.
Methods
One thousand two hundred and fifty patients with newly diagnosed brain metastases (BM) were identified from the Vienna Brain Metastasis Registry.
Results
PLR and CRP/Alb were higher in patients with progressive extracranial disease and lower in patients with no evidence of extracranial disease. Lower NLR (cut-off = 5.07; 9.3 vs. 5.0 months), LLR (cut-off = 5.76; 10.0 vs. 5.3 months), PLR (cut-off = 335; 8.0 vs. 3.8 months), MLR (cut-off = 0.53; 6.0 vs. 3.5 months) and CRP/Alb (cut-off = 2.93; 8.5 vs. 3.7 months;
p
adj
|
| doi_str_mv | 10.1038/s41416-020-01254-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8007827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2506709237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-6186d6e1ac087e08c9192a48f0211d4d725b23375c380e5d9ebe29594f2251a73</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhS1ERS-FP8ACRWLDJnT8SJxskFBVHlKlLoC15etMbl0ldvAkt7r_Hl9SymNRybJlzXeOZ3wYe8XhHQfZnJPiitclCCiBi0qV8IRteCVFyRuhn7INAOgSWgGn7DnRbb620Ohn7FRKpSXXsGHT1wPNOHpX-NAPdhzt7GMoyMWEVOQ94WBnLO78fFPQkvZ-b4diSnEXInnKqmLKEgwzrUzAu-FQdN4eAeyKbbKZGXG2lBfSC3bS24Hw5f15xr5_vPx28bm8uv705eLDVemUVnNZ86buauTW5Y4RGtfyVljV9CA471SnRbUVUurKyQaw6lrcomirVvVCVNxqecber77Tsh2xc7nDZAczJT_adDDRevNvJfgbs4t70-RPy9-XDd7eG6T4Y0GazejJ4TDYgHEhI5RutVK15Bl98x96G5cU8nhGVFDrHIE8GoqVcikSJewfmuFgjoGaNVCTAzW_AjWQRa__HuNB8jvBDMgVoFwKO0x_3n7E9idfbK3-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506709237</pqid></control><display><type>article</type><title>Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Starzer, Angelika M. ; Steindl, Ariane ; Mair, Maximilian J. ; Deischinger, Carola ; Simonovska, Anika ; Widhalm, Georg ; Gatterbauer, Brigitte ; Dieckmann, Karin ; Heller, Gerwin ; Preusser, Matthias ; Berghoff, Anna S.</creator><creatorcontrib>Starzer, Angelika M. ; Steindl, Ariane ; Mair, Maximilian J. ; Deischinger, Carola ; Simonovska, Anika ; Widhalm, Georg ; Gatterbauer, Brigitte ; Dieckmann, Karin ; Heller, Gerwin ; Preusser, Matthias ; Berghoff, Anna S.</creatorcontrib><description>Background
Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial solid cancer.
Methods
One thousand two hundred and fifty patients with newly diagnosed brain metastases (BM) were identified from the Vienna Brain Metastasis Registry.
Results
PLR and CRP/Alb were higher in patients with progressive extracranial disease and lower in patients with no evidence of extracranial disease. Lower NLR (cut-off = 5.07; 9.3 vs. 5.0 months), LLR (cut-off = 5.76; 10.0 vs. 5.3 months), PLR (cut-off = 335; 8.0 vs. 3.8 months), MLR (cut-off = 0.53; 6.0 vs. 3.5 months) and CRP/Alb (cut-off = 2.93; 8.5 vs. 3.7 months;
p
adj
< 0.05) were associated with longer overall survival (OS). In multivariate analysis with graded prognostic assessment (hazard ratio (HR) 1.45; 95% confidence interval (CI): 1.32–1.59;
p
adj
= 1.62e − 13
)
, NLR (HR 1.55; 95% CI: 1.38–1.75;
p
adj
= 1.92e − 11), LLR (HR 1.57; 95% CI: 1.39–1.77;
p
adj
= 1.96e − 11
)
, PLR (HR 1.60; 95% CI: 1.39–1.85;
p
adj
= 2.87955e − 9), MLR (HR 1.41; 95% CI: 1.14–1.75;
p
adj
= 0.027) and CRP/Alb (HR 1.83; 95% CI: 1.54–2.18;
p
adj
= 2.73e − 10) remained independent factors associated with OS at BM diagnosis.
Conclusions
Systemic inflammation, measured by NLR, LLR, PLR, MLR and CRP/Alb, was associated with OS in patients with BM. Further exploration of immune modulating therapies is warranted in the setting of BM.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-01254-0</identifier><identifier>PMID: 33473170</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/409 ; 692/4028/67/1922 ; 692/53/2422 ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor - analysis ; Biomedical and Life Sciences ; Biomedicine ; Blood Platelets - pathology ; Brain cancer ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Brain Neoplasms - therapy ; Cancer Research ; Combined Modality Therapy ; Drug Resistance ; Epidemiology ; Female ; Follow-Up Studies ; Humans ; Inflammation ; Inflammation Mediators - analysis ; Leukocytes (neutrophilic) ; Lymphocytes ; Lymphocytes - pathology ; Medical prognosis ; Metastases ; Metastasis ; Middle Aged ; Molecular Medicine ; Monocytes ; Multivariate analysis ; Neoplasms - mortality ; Neoplasms - pathology ; Neoplasms - therapy ; Neutrophils - pathology ; Oncology ; Prognosis ; Retrospective Studies ; Survival Rate ; Young Adult</subject><ispartof>British journal of cancer, 2021-03, Vol.124 (7), p.1294-1300</ispartof><rights>The Author(s), under exclusive licence to The Author(s), under exclusive licence to Cancer Research UK 2021</rights><rights>The Author(s), under exclusive licence to The Author(s), under exclusive licence to Cancer Research UK 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-6186d6e1ac087e08c9192a48f0211d4d725b23375c380e5d9ebe29594f2251a73</citedby><cites>FETCH-LOGICAL-c474t-6186d6e1ac087e08c9192a48f0211d4d725b23375c380e5d9ebe29594f2251a73</cites><orcidid>0000-0002-6537-3874 ; 0000-0001-9379-6797 ; 0000-0001-8742-5631</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007827/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007827/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33473170$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Starzer, Angelika M.</creatorcontrib><creatorcontrib>Steindl, Ariane</creatorcontrib><creatorcontrib>Mair, Maximilian J.</creatorcontrib><creatorcontrib>Deischinger, Carola</creatorcontrib><creatorcontrib>Simonovska, Anika</creatorcontrib><creatorcontrib>Widhalm, Georg</creatorcontrib><creatorcontrib>Gatterbauer, Brigitte</creatorcontrib><creatorcontrib>Dieckmann, Karin</creatorcontrib><creatorcontrib>Heller, Gerwin</creatorcontrib><creatorcontrib>Preusser, Matthias</creatorcontrib><creatorcontrib>Berghoff, Anna S.</creatorcontrib><title>Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial solid cancer.
Methods
One thousand two hundred and fifty patients with newly diagnosed brain metastases (BM) were identified from the Vienna Brain Metastasis Registry.
Results
PLR and CRP/Alb were higher in patients with progressive extracranial disease and lower in patients with no evidence of extracranial disease. Lower NLR (cut-off = 5.07; 9.3 vs. 5.0 months), LLR (cut-off = 5.76; 10.0 vs. 5.3 months), PLR (cut-off = 335; 8.0 vs. 3.8 months), MLR (cut-off = 0.53; 6.0 vs. 3.5 months) and CRP/Alb (cut-off = 2.93; 8.5 vs. 3.7 months;
p
adj
< 0.05) were associated with longer overall survival (OS). In multivariate analysis with graded prognostic assessment (hazard ratio (HR) 1.45; 95% confidence interval (CI): 1.32–1.59;
p
adj
= 1.62e − 13
)
, NLR (HR 1.55; 95% CI: 1.38–1.75;
p
adj
= 1.92e − 11), LLR (HR 1.57; 95% CI: 1.39–1.77;
p
adj
= 1.96e − 11
)
, PLR (HR 1.60; 95% CI: 1.39–1.85;
p
adj
= 2.87955e − 9), MLR (HR 1.41; 95% CI: 1.14–1.75;
p
adj
= 0.027) and CRP/Alb (HR 1.83; 95% CI: 1.54–2.18;
p
adj
= 2.73e − 10) remained independent factors associated with OS at BM diagnosis.
Conclusions
Systemic inflammation, measured by NLR, LLR, PLR, MLR and CRP/Alb, was associated with OS in patients with BM. Further exploration of immune modulating therapies is warranted in the setting of BM.</description><subject>692/308/409</subject><subject>692/4028/67/1922</subject><subject>692/53/2422</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood Platelets - pathology</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - therapy</subject><subject>Cancer Research</subject><subject>Combined Modality Therapy</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation Mediators - analysis</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Monocytes</subject><subject>Multivariate analysis</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>Neutrophils - pathology</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtv1TAQhS1ERS-FP8ACRWLDJnT8SJxskFBVHlKlLoC15etMbl0ldvAkt7r_Hl9SymNRybJlzXeOZ3wYe8XhHQfZnJPiitclCCiBi0qV8IRteCVFyRuhn7INAOgSWgGn7DnRbb620Ohn7FRKpSXXsGHT1wPNOHpX-NAPdhzt7GMoyMWEVOQ94WBnLO78fFPQkvZ-b4diSnEXInnKqmLKEgwzrUzAu-FQdN4eAeyKbbKZGXG2lBfSC3bS24Hw5f15xr5_vPx28bm8uv705eLDVemUVnNZ86buauTW5Y4RGtfyVljV9CA471SnRbUVUurKyQaw6lrcomirVvVCVNxqecber77Tsh2xc7nDZAczJT_adDDRevNvJfgbs4t70-RPy9-XDd7eG6T4Y0GazejJ4TDYgHEhI5RutVK15Bl98x96G5cU8nhGVFDrHIE8GoqVcikSJewfmuFgjoGaNVCTAzW_AjWQRa__HuNB8jvBDMgVoFwKO0x_3n7E9idfbK3-</recordid><startdate>20210330</startdate><enddate>20210330</enddate><creator>Starzer, Angelika M.</creator><creator>Steindl, Ariane</creator><creator>Mair, Maximilian J.</creator><creator>Deischinger, Carola</creator><creator>Simonovska, Anika</creator><creator>Widhalm, Georg</creator><creator>Gatterbauer, Brigitte</creator><creator>Dieckmann, Karin</creator><creator>Heller, Gerwin</creator><creator>Preusser, Matthias</creator><creator>Berghoff, Anna S.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6537-3874</orcidid><orcidid>https://orcid.org/0000-0001-9379-6797</orcidid><orcidid>https://orcid.org/0000-0001-8742-5631</orcidid></search><sort><creationdate>20210330</creationdate><title>Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases</title><author>Starzer, Angelika M. ; Steindl, Ariane ; Mair, Maximilian J. ; Deischinger, Carola ; Simonovska, Anika ; Widhalm, Georg ; Gatterbauer, Brigitte ; Dieckmann, Karin ; Heller, Gerwin ; Preusser, Matthias ; Berghoff, Anna S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-6186d6e1ac087e08c9192a48f0211d4d725b23375c380e5d9ebe29594f2251a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/308/409</topic><topic>692/4028/67/1922</topic><topic>692/53/2422</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood Platelets - pathology</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - therapy</topic><topic>Cancer Research</topic><topic>Combined Modality Therapy</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation Mediators - analysis</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Monocytes</topic><topic>Multivariate analysis</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>Neutrophils - pathology</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Starzer, Angelika M.</creatorcontrib><creatorcontrib>Steindl, Ariane</creatorcontrib><creatorcontrib>Mair, Maximilian J.</creatorcontrib><creatorcontrib>Deischinger, Carola</creatorcontrib><creatorcontrib>Simonovska, Anika</creatorcontrib><creatorcontrib>Widhalm, Georg</creatorcontrib><creatorcontrib>Gatterbauer, Brigitte</creatorcontrib><creatorcontrib>Dieckmann, Karin</creatorcontrib><creatorcontrib>Heller, Gerwin</creatorcontrib><creatorcontrib>Preusser, Matthias</creatorcontrib><creatorcontrib>Berghoff, Anna S.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Starzer, Angelika M.</au><au>Steindl, Ariane</au><au>Mair, Maximilian J.</au><au>Deischinger, Carola</au><au>Simonovska, Anika</au><au>Widhalm, Georg</au><au>Gatterbauer, Brigitte</au><au>Dieckmann, Karin</au><au>Heller, Gerwin</au><au>Preusser, Matthias</au><au>Berghoff, Anna S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2021-03-30</date><risdate>2021</risdate><volume>124</volume><issue>7</issue><spage>1294</spage><epage>1300</epage><pages>1294-1300</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
Systemic inflammation measured by the neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and CRP/albumin ratio (CRP/Alb) was shown to impact the survival prognosis in patients with extracranial solid cancer.
Methods
One thousand two hundred and fifty patients with newly diagnosed brain metastases (BM) were identified from the Vienna Brain Metastasis Registry.
Results
PLR and CRP/Alb were higher in patients with progressive extracranial disease and lower in patients with no evidence of extracranial disease. Lower NLR (cut-off = 5.07; 9.3 vs. 5.0 months), LLR (cut-off = 5.76; 10.0 vs. 5.3 months), PLR (cut-off = 335; 8.0 vs. 3.8 months), MLR (cut-off = 0.53; 6.0 vs. 3.5 months) and CRP/Alb (cut-off = 2.93; 8.5 vs. 3.7 months;
p
adj
< 0.05) were associated with longer overall survival (OS). In multivariate analysis with graded prognostic assessment (hazard ratio (HR) 1.45; 95% confidence interval (CI): 1.32–1.59;
p
adj
= 1.62e − 13
)
, NLR (HR 1.55; 95% CI: 1.38–1.75;
p
adj
= 1.92e − 11), LLR (HR 1.57; 95% CI: 1.39–1.77;
p
adj
= 1.96e − 11
)
, PLR (HR 1.60; 95% CI: 1.39–1.85;
p
adj
= 2.87955e − 9), MLR (HR 1.41; 95% CI: 1.14–1.75;
p
adj
= 0.027) and CRP/Alb (HR 1.83; 95% CI: 1.54–2.18;
p
adj
= 2.73e − 10) remained independent factors associated with OS at BM diagnosis.
Conclusions
Systemic inflammation, measured by NLR, LLR, PLR, MLR and CRP/Alb, was associated with OS in patients with BM. Further exploration of immune modulating therapies is warranted in the setting of BM.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33473170</pmid><doi>10.1038/s41416-020-01254-0</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6537-3874</orcidid><orcidid>https://orcid.org/0000-0001-9379-6797</orcidid><orcidid>https://orcid.org/0000-0001-8742-5631</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2021-03, Vol.124 (7), p.1294-1300 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8007827 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | 692/308/409 692/4028/67/1922 692/53/2422 Adult Aged Aged, 80 and over Biomarkers, Tumor - analysis Biomedical and Life Sciences Biomedicine Blood Platelets - pathology Brain cancer Brain Neoplasms - mortality Brain Neoplasms - secondary Brain Neoplasms - therapy Cancer Research Combined Modality Therapy Drug Resistance Epidemiology Female Follow-Up Studies Humans Inflammation Inflammation Mediators - analysis Leukocytes (neutrophilic) Lymphocytes Lymphocytes - pathology Medical prognosis Metastases Metastasis Middle Aged Molecular Medicine Monocytes Multivariate analysis Neoplasms - mortality Neoplasms - pathology Neoplasms - therapy Neutrophils - pathology Oncology Prognosis Retrospective Studies Survival Rate Young Adult |
| title | Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T19%3A50%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20inflammation%20scores%20correlate%20with%20survival%20prognosis%20in%20patients%20with%20newly%20diagnosed%20brain%20metastases&rft.jtitle=British%20journal%20of%20cancer&rft.au=Starzer,%20Angelika%20M.&rft.date=2021-03-30&rft.volume=124&rft.issue=7&rft.spage=1294&rft.epage=1300&rft.pages=1294-1300&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-01254-0&rft_dat=%3Cproquest_pubme%3E2506709237%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506709237&rft_id=info:pmid/33473170&rfr_iscdi=true |